Organon (OGN) EGM 2026 summary

Opening remarks and agenda

• The meeting was called to order by the Executive Chair, with board members, executive leadership, and independent auditors present.

• Procedures for virtual participation, voting, and question submission were reviewed.

• The agenda was limited to proposals described in the notice and proxy statement.

Specific resolutions to be voted on

• Adoption of the merger agreement with Sun Pharmaceutical Holdings USA, Inc. and its subsidiary.

• Approval, on a non-binding advisory basis, of compensation for named executive officers related to the merger.

Corporate governance

• Quorum was established with 74.5% of voting power represented.

• Inspector of Election and procedures for voting and proxies were confirmed.